Cargando…

Histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction

AIMS: Cancer therapy‐related cardiac dysfunction (CTRCD) is commonly reported, but its histopathology, mechanisms, and risk factors are not known. We aimed to clarify the histopathology and mechanisms of CTRCD to identify risk factors. METHODS AND RESULTS: We performed myocardial histopathological s...

Descripción completa

Detalles Bibliográficos
Autores principales: Terada, Chiyoko‐Ikeda, Onoue, Kenji, Fujii, Tomomi, Itami, Hiroe, Morita, Kohei, Uchiyama, Tomoko, Takeda, Maiko, Nakagawa, Hitoshi, Nakano, Tomoya, Baba, Youichirou, Amemiya, Kisaki, Saito, Yoshihiko, Hatakeyama, Kinta, Ohbayashi, Chiho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715834/
https://www.ncbi.nlm.nih.gov/pubmed/35747987
http://dx.doi.org/10.1002/ehf2.14034
_version_ 1784842545959796736
author Terada, Chiyoko‐Ikeda
Onoue, Kenji
Fujii, Tomomi
Itami, Hiroe
Morita, Kohei
Uchiyama, Tomoko
Takeda, Maiko
Nakagawa, Hitoshi
Nakano, Tomoya
Baba, Youichirou
Amemiya, Kisaki
Saito, Yoshihiko
Hatakeyama, Kinta
Ohbayashi, Chiho
author_facet Terada, Chiyoko‐Ikeda
Onoue, Kenji
Fujii, Tomomi
Itami, Hiroe
Morita, Kohei
Uchiyama, Tomoko
Takeda, Maiko
Nakagawa, Hitoshi
Nakano, Tomoya
Baba, Youichirou
Amemiya, Kisaki
Saito, Yoshihiko
Hatakeyama, Kinta
Ohbayashi, Chiho
author_sort Terada, Chiyoko‐Ikeda
collection PubMed
description AIMS: Cancer therapy‐related cardiac dysfunction (CTRCD) is commonly reported, but its histopathology, mechanisms, and risk factors are not known. We aimed to clarify the histopathology and mechanisms of CTRCD to identify risk factors. METHODS AND RESULTS: We performed myocardial histopathological studies on 13 endomyocardial biopsies from CTRCD patients, 35 autopsied cancer cases with or without cardiac dysfunction, and controls without cancer (10 biopsies and 9 autopsies). Cardiotoxicity risk scores were calculated based on medication; and patient‐related risk factors, fibrosis, and cardiomyocyte changes were scored; and p53 and H3K27ac histone modification were evaluated by histological score (H‐score). In the biopsy cases, all histopathological changes and the p53 evaluation were significantly higher in the CTRCD group than in the controls [p53 H‐score; 63 (9.109) vs. 33 (5.099), P < 0.05]. In patients with a short time between drug and disease onset (<4.2 years), fibrosis and p53 positively correlated (r = 0.76, P < 0.05), and in those with late onset disease (>4.2 years), cellular abnormalities and p53 trended to a positive correlation and cardiotoxicity risk scores and p53 positively correlated (r = 0.95, P < 0.05). A year after biopsy, the short‐term group had significant recovery of ejection fraction compared with the long‐term group (P < 0.05). The CTRCD group had a significantly worse overall survival prognosis than the control group [hazard ratio 7.61 (95% confidence interval 1.30–44.6), P < 0.05]. Autopsy cases with cancer treatment also had a high grade of histopathological changes, with even more severe changes in patients with cardiac dysfunction, and had increased p53 and H3K27ac expression levels, compared with controls. H‐scores of p53 and H3K27ac showed a positive correlation in the CTRCD group in biopsy cases (r = 0.62, P < 0.05) and a positive correlation in autopsy cases. CONCLUSIONS: Our results indicate distinct morphological characteristics in myocardial histopathology associated with CTRCD. p53 and H3K27ac histone modification could be sensitive markers of CTRCD and suggest a mechanistic involvement of epigenetic changes.
format Online
Article
Text
id pubmed-9715834
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97158342022-12-05 Histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction Terada, Chiyoko‐Ikeda Onoue, Kenji Fujii, Tomomi Itami, Hiroe Morita, Kohei Uchiyama, Tomoko Takeda, Maiko Nakagawa, Hitoshi Nakano, Tomoya Baba, Youichirou Amemiya, Kisaki Saito, Yoshihiko Hatakeyama, Kinta Ohbayashi, Chiho ESC Heart Fail Original Articles AIMS: Cancer therapy‐related cardiac dysfunction (CTRCD) is commonly reported, but its histopathology, mechanisms, and risk factors are not known. We aimed to clarify the histopathology and mechanisms of CTRCD to identify risk factors. METHODS AND RESULTS: We performed myocardial histopathological studies on 13 endomyocardial biopsies from CTRCD patients, 35 autopsied cancer cases with or without cardiac dysfunction, and controls without cancer (10 biopsies and 9 autopsies). Cardiotoxicity risk scores were calculated based on medication; and patient‐related risk factors, fibrosis, and cardiomyocyte changes were scored; and p53 and H3K27ac histone modification were evaluated by histological score (H‐score). In the biopsy cases, all histopathological changes and the p53 evaluation were significantly higher in the CTRCD group than in the controls [p53 H‐score; 63 (9.109) vs. 33 (5.099), P < 0.05]. In patients with a short time between drug and disease onset (<4.2 years), fibrosis and p53 positively correlated (r = 0.76, P < 0.05), and in those with late onset disease (>4.2 years), cellular abnormalities and p53 trended to a positive correlation and cardiotoxicity risk scores and p53 positively correlated (r = 0.95, P < 0.05). A year after biopsy, the short‐term group had significant recovery of ejection fraction compared with the long‐term group (P < 0.05). The CTRCD group had a significantly worse overall survival prognosis than the control group [hazard ratio 7.61 (95% confidence interval 1.30–44.6), P < 0.05]. Autopsy cases with cancer treatment also had a high grade of histopathological changes, with even more severe changes in patients with cardiac dysfunction, and had increased p53 and H3K27ac expression levels, compared with controls. H‐scores of p53 and H3K27ac showed a positive correlation in the CTRCD group in biopsy cases (r = 0.62, P < 0.05) and a positive correlation in autopsy cases. CONCLUSIONS: Our results indicate distinct morphological characteristics in myocardial histopathology associated with CTRCD. p53 and H3K27ac histone modification could be sensitive markers of CTRCD and suggest a mechanistic involvement of epigenetic changes. John Wiley and Sons Inc. 2022-06-23 /pmc/articles/PMC9715834/ /pubmed/35747987 http://dx.doi.org/10.1002/ehf2.14034 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Terada, Chiyoko‐Ikeda
Onoue, Kenji
Fujii, Tomomi
Itami, Hiroe
Morita, Kohei
Uchiyama, Tomoko
Takeda, Maiko
Nakagawa, Hitoshi
Nakano, Tomoya
Baba, Youichirou
Amemiya, Kisaki
Saito, Yoshihiko
Hatakeyama, Kinta
Ohbayashi, Chiho
Histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction
title Histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction
title_full Histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction
title_fullStr Histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction
title_full_unstemmed Histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction
title_short Histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction
title_sort histopathological and epigenetic changes in myocardium associated with cancer therapy‐related cardiac dysfunction
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715834/
https://www.ncbi.nlm.nih.gov/pubmed/35747987
http://dx.doi.org/10.1002/ehf2.14034
work_keys_str_mv AT teradachiyokoikeda histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT onouekenji histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT fujiitomomi histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT itamihiroe histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT moritakohei histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT uchiyamatomoko histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT takedamaiko histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT nakagawahitoshi histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT nakanotomoya histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT babayouichirou histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT amemiyakisaki histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT saitoyoshihiko histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT hatakeyamakinta histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction
AT ohbayashichiho histopathologicalandepigeneticchangesinmyocardiumassociatedwithcancertherapyrelatedcardiacdysfunction